(1R)-1-(4-sulfanylphenyl)ethanol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯硫酚类
• 英文名称: (1R)-1-(4-sulfanylphenyl)ethanol
• 化学式: C₈H₁₀OS
• 分子量: 154.23
• InChiKey: OEFNBHQZFVQRJR-ZCFIWIBFSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  21.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Dihydropyrazolopyrimidinone compounds as PDE2 inhibitors
  申请人：Merck Sharp & Dohme Corp.

  公开号：US10174037B2

  公开（公告）日：2019-01-08

  The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及式（I）的二氢吡唑嘧啶酮化合物，该化合物可作为治疗剂用于治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病。本发明还涉及使用此类化合物治疗神经和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能减退或基底节功能障碍相关的疾病。
• DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：US20180148453A1

  公开（公告）日：2018-05-31

  The present invention is directed to dihydropyrazolopyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.